MTOR and breast cancer: Lu et al. [29] found that the noncoding RNA-regulator of reprogramming (ROR) enhanced the sensitivity of breast cancer cells to the chemotherapeutic drug tamoxifen through inhibition of the PI3K/AKT/mTOR signaling pathway.